Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$261.3MCash, Jun 2026
19moCash Runway (est.)
+2%Share Count, 1 Year
Follow UPB by emailGet an email when UPB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about UPB, unsubscribe in one click. Privacy
📣 What UPB Says Is Next
first quarter of 2027 · “Upstream Bio remains on track to initiate Phase 3 clinical trials in severe asthma and CRSwNP in the first quarter of 2027.”
Company press release, Sep 1, 2026 · SEC filing
second half of 2027 · “Data from the study are expected in the second half of 2027.”
Company press release, Aug 11, 2026 · SEC filing
first quarter of 2027 · “Upcoming Initiation of Phase 3 Trials in Severe Asthma and CRSwNP o The Company remains on track to initiate Phase 3 clinical trials in severe asthma and CRSwNP in the first quarter of 2027. o End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for both severe asthma and CRSwNP are on track.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
UPB reported $261.3M in cash and short-term investments (as of Jun 30, 2026) and used about $42.1M/quarter in operations, an estimated runway of 18.6 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UPB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.